

56. An Efficient Synthesis of Optically Pure (*R*)- and (*S*)-2-(Aminomethyl)alanine ((*R*)- and (*S*)-Ama) and (*R*)- and (*S*)-2-(Aminomethyl)leucine ((*R*)- and (*S*)-Aml)

by Daniel Obrecht*, Helena Karajannis¹), Christian Lehmann, Peter Schönholzer,
Clive Spiegler²), and Klaus Müller


F. Hoffmann-La Roche AG, Pharma Research, CH-4002 Basel

Dedicated to Prof. M. Hesse on the occasion of his 60th birthday

(30. XII. 94)

An efficient synthesis of enantiomerically pure (*R*)- and (*S*)-2-(aminomethyl)alanine ((*R*)- and (*S*)-Ama) **1a** and (*R*)- and (*S*)-2-(aminomethyl)leucine ((*R*)- and (*S*)-Aml) **1b** is described (Schemes 1 and 2). Resolution of the racemic amino acids was achieved using L-phenylalanine cyclohexylamide (**2**) as chiral auxiliary. The free amino acids **1a, b** were converted to the *N*²-Boc, *N*¹-Z-protected derivatives **11a, b** (Scheme 3) ready for incorporation into peptides. Based on the three crystal structures of the diastereoisomeric peptides **8a, 8b**, and **9b**, the absolute configurations in both series were determined. β -Turn type-I geometries were observed for structures **8b** and **9b**, whereas **8a** crystallized in an extended backbone conformation.

1. Introduction. – As part of our program to study the conformational properties of novel and interesting α, α -disubstituted amino acids in small peptides, we were faced with the problem to develop an efficient and quick synthesis of optically pure (*R*)- and (*S*)-2-(aminomethyl)alanine ((*R*)- and (*S*)-Ama = L and D-Ala(2-NH₂CH₂), resp.) **1a** and (*R*)- and (*S*)-2-(aminomethyl)leucine ((*R*)- and (*S*)-Aml = L and D-Leu(2-NH₂CH₂), resp.) **1b**.




We were especially interested to investigate whether building blocks of type **1** can stabilize α -helical conformations in peptides, due to their amphiphilic character combined with the known inherent propensities of certain α, α -disubstituted amino acids to stabilize β -turn and α -helical conformations [1] [2].

2. Synthesis of (*R*)- and (*S*)-Ama and (*R*)- and (*S*)-Aml. – Recently, we reported a general synthesis of optically pure (*R*)- and (*S*)- α, α -disubstituted amino acids [2–4], using L-phenylalanine cyclohexylamide (**2**) as chiral auxiliary. The synthesis of (*R*)- and (*S*)-Ama and (*R*)- and (*S*)-Aml following this approach is outlined in Schemes 1 and 2.

¹) Part of Ph. D. thesis of H. K., University of Bern, 1994.

²) Part of Ph. D. thesis of C. S., University of Zürich, 1993.




i) **2**, NMP, 50–80°. *ii)* CF₃SO₃H, toluene, 50°; then MeOH, r.t.; then 3N aq. NaOH, dioxane/H₂O or LiOH·H₂O, THF/MeOH/H₂O. *iii)* 25% aq. HCl, dioxane, 100°.

3. Selective Protection of the Two Amino Groups of (R)- and (S)-Ama and (R)- and (S)-Aml. – For the use of the amino acids (R)- and (S)-Ama **1a** and (R)- and (S)-Aml **1b** in peptide synthesis, an efficient protocol for the selective protection of the two amino groups had to be devised. Our strategy is shown in Scheme 3.

Selective Z protection of the 2-aminomethyl groups in (R)- and (S)-Ama **1a** and (R)- and (S)-Aml **1b** was achieved by slow addition of 1.2 equiv. of *N*-[(benzyloxy)carbonyloxy]succinimide (Z-OSu) in dioxane to a solution of **1a** or **1b** in aqueous Na₂CO₃ solution at temperatures below 0° to yield the monoprotected amino acids (R)- and (S)-**10a** and (R)- and (S)-**10b** (Scheme 3). Subsequent Boc protection of the 2-amino groups could be effected once again by using the *Kricheldorf* method [7] which gave the fully protected amino-acid building blocks (R)- and (S)-**11a** and (R)- and (S)-**11b** in optically pure form and ready for incorporation into peptides.

Scheme 3



i) Na_2CO_3 , H_2O , dioxane, Z-OSu , $-20 \rightarrow 0^\circ$. *ii*) Me_3SiCl , CH_2Cl_2 ; then $(i\text{-Pr})_2\text{NEt}$, Boc_2O , Δ .

4. Absolute Configurations of (*R*)- and (*S*)-Ama 1a and (*R*)- and (*S*)-Aml 1b and Discussion of the Conformational Characteristics of 8a and 9b in the Crystalline State. – In the case of the alanine series, crystallization and X-ray structure determination for one diastereoisomer, the (*R,S*)-Ama derivative **8a**, allowed us to determine the absolute configuration by means of the internal chiral reference of L-phenylalanine (*cf.* Fig. 1). For the leucine series, both diastereoisomers, the (*R,S*)- and (*S,S*)-Aml derivatives **8b** and **9b**, could be crystallized and analyzed (*cf.* Figs. 2 and 3, resp.).

It is of interest to note that both epimeric leucine derivatives **8b** and **9b** adopt β -turn type-I geometries with a main chain $\text{C}=\text{O} \cdots \text{H}-\text{N}$ H-bond, despite the inversion of



Fig. 1. Stereoscopic projection of the X-ray structure of (*R*)-2-(aminomethyl)alanine ((*R*)-Ama) derivative **8a**




Fig. 2. Stereoscopic projection of the X-ray structure of (*R*)-2-(aminomethyl)leucine ((*R*)-Aml) derivative **8b**




Fig. 3. Stereoscopic projection of the X-ray structure of (*S*)-2-(aminomethyl)leucine ((*S*)-Aml) derivative **9b**

configuration at the C(α) atom of the first amino acid (Fig. 4). The (*N*-benzoylamino)-methyl side chains, however, fold back onto the main chain in two different ways: In the (*R*)-epimer **8b**, a short turn involving the side chain amide H-atom and the C=O group of the N-terminal benzoyl unit is formed, whereas in the (*S*)-epimer **9b**, the side chain benzoyl C=O group accepts a H-bond from the main-chain amide unit. Both H-bonded turns between main-chain and side-chain amide units can be classified as 2_7 -turns [12]. This structural element does, however, not conform to either a classical or an inverse γ -turn [13]. An analogous folding of side chains onto their own N z is observed for 3% of Glx (Gln and Glu) residues in a representative set of well resolved protein X-ray structures [14]. By contrast, the (*R,S*)-Ama diastereoisomer **8a** adopts an extended main chain with a H-bonded turn-like fold involving the aminomethyl side chain. This main-chain conformation seems to be found only in conjunction with unusual amino-acid residues, since it could not be identified in proteins [10] [15–17]. Interestingly, this conformation does not correspond to a minimum on the energy surface determined by recent *ab initio* calculations [18]; however, the related conformation termed $\alpha_D e_L$ by those authors is a stable minimum in the force field ECEPP/2 ([18] and ref. cit. therein) as well as in our in-house force field MAB [19].

<p style="text-align: right;">8a</p>	<p>d_1 2.787 d_2 3.051</p> <p>ϕ_{i-1} +64.3 χ_{i+1}^1 -54.2 ψ_{i-1} +26.7 χ_{i+1}^2 +96.7 ϕ_{i+2} -76.5 χ_{i+2}^1 +51.6 ψ_{i+2} +176.3 χ_{i+2}^2 +84.9</p> <p>MAIN CHAIN: EXTENDED <i>($\nu\beta_b$ [10])</i></p> <p>SIDE CHAIN: reverse-2γ3γ-TURN</p>
<p style="text-align: right;">8b</p>	<p>d_1 2.948 $\chi_{i+1,1}^1$ -58.4 d_2 2.848 $\chi_{i+1,1}^2$ +179.5</p> <p>ϕ_{i+1} -43.0 $\chi_{i+1,2}^1$ -176.6 ψ_{i+1} -41.9 $\chi_{i+1,2}^2$ -84.6 ϕ_{i+2} -84.4 χ_{i+2}^1 -71.8 ψ_{i+2} +0.5 χ_{i+2}^2 -65.3</p> <p>MAIN CHAIN: β-TURN TYPE I <i>($\alpha\alpha$ [10])</i></p> <p>SIDE CHAIN: reverse-2γ-TURN <i>(two molecules in asymmetric unit; very close geometry with same turn characteristics)</i></p>
<p style="text-align: right;">9b</p>	<p>d_1 2.953 $\chi_{i+1,1}^1$ +65.3 d_2 2.852 $\chi_{i+1,1}^2$ -87.0</p> <p>ϕ_{i+1} -60.2 $\chi_{i+1,2}^1$ +69.0 ψ_{i+1} -28.0 $\chi_{i+1,2}^2$ -60.9 ϕ_{i+2} -73.6 χ_{i+2}^1 +49.9 ψ_{i+2} -16.1 χ_{i+2}^2 -89.3</p> <p>MAIN CHAIN: β-TURN TYPE I <i>($\alpha\alpha$ [10])</i></p> <p>SIDE CHAIN: 2γ-TURN</p>

Fig. 4. Conformational characteristics of the crystalline branched tetraamides **8a**, **8b**, and **9b**. Designation of torsional angles according to IUPAC-IUB recommendations [11].

The authors would like to thank their colleagues from *F. Hoffmann-La Roche AG*, for IR (Mr. *A. Bubendorf*), NMR (Dr. *W. Arnold*), MS (Dr. *W. Vetter* and Mr. *W. Meister*), and elemental analyses (Dr. *S. Müller*). We would like to thank Profs. Drs. *H. Heimgartner*, *H.-J. Hansen*, *A. Vasella*, and *J. Baldwin* for fruitful discussions and valuable pieces of advice.

Experimental Part

General. All reactions with air- or moisture-sensitive reactants and solvents were carried out in oven- or flame-dried glassware under a positive pressure of dry Ar. Reaction solvents and liquid reagents were purified by distillation shortly before use. THF was distilled under Ar from Na with benzophenone ketyl as indicator, CH_2Cl_2 from powdered CaH_2 , and DMF over ninhydrin and kept over 4 Å molecular sieves. All other reactants were 'reagent-grade' unless described otherwise. Anal. TLC: 2.5 × 10 cm precoated TLC plates, SiO_2 60F-254, layer thickness 0.25 mm (*E. Merck & Co.*, Darmstadt, Germany). Flash chromatography (FC): *E. Merck* SiO_2 60 (230–400 mesh ASTM); according to [7]. M.p.: *Büchi-SMP-20* apparatus; uncorrected. IR Spectra: *Nicolet-7199-FT* spectrophotometer; solids in KBr pellets, liquids as thin films; characteristic bands in cm^{-1} . $^1\text{H-NMR}$ Spectra: *Bruker-AC-250* apparatus, at 250 MHz; in CDCl_3 ; SiMe_4 as internal standard; chemical shifts of signal centres and ranges in ppm (δ), J in Hz. MS: FAB = fast-atom-bombardment ionization, ISP = ion-spray ionization, positive mode, ISN = ion-spray ionization, negative mode.

rac-2,3-Diamino-2-methylpropanoic Acid (rac-1a). To a stirred suspension of *rac-5a* (11.5 g, 47.5 mmol) in CH_2Cl_2 (75 ml) was added CF_3COOH (50 ml) at 0°, and the mixture was stirred for 3 h at 0°. After evaporation, the solid residue was dried under reduced pressure, suspended in Et_2O (100 ml), filtered, and dried under reduced pressure: 11.5 g (100%) of *rac-5-(aminomethyl)-5-methylimidazolidin-2,4-dione trifluoroacetate*. White solid. M.p. (dec.) > 238°. IR (KBr): 3375w (br.), 3164m (br.), 3081m (br.), 1823m, 1728s, 1672s, 1626m, 1554m, 1418m, 1390w, 1341w, 1282w, 1205m, 1154m, 1150w, 1170w, 723w. $^1\text{H-NMR}$ (D_6)DMSO, 250 MHz): 5.98 (br. s, NH); 7.93 (s, NH); 3.11, 2.92 (2d, AB, J_{AB} = 13.5, CH_2); 1.33 (s, Me). MS: 143 (< 1, M^+ (free amine)), 114 (20), 69 (16), 45 (23), 30 (100).

A mixture of this trifluoroacetate (11.5 g, 47.5 mmol) and $\text{Ba}(\text{OH})_2 \cdot 8 \text{H}_2\text{O}$ (59.95 g, 190 mmol) in H_2O (140 ml) was stirred for 48 h at 140° in a steel autoclave, cooled to r.t., and acidified by addition of 4N aq. H_2SO_4 (50 ml). The suspension was vigorously stirred and heated for 1 h on a steam bath, the precipitate (BaSO_4) filtered, and the residue washed with H_2O . The filtrate was evaporated to ca. 50 ml and chromatographed on *Bio-A6-50W-X8* ion-exchange resin (100 g). After the column was washed with H_2O to pH 7, the product was eluted with 0.5N aq. NH_3 to give, after lyophilization and drying over P_2O_5 under reduced pressure, 4.7 g (84%) of *rac-1a*. White powder. M.p. 229–230°. IR (KBr): 3420w (br.), 3343s, 3091m, 3000m, 2971m, 2941s, 2877m, 2681m, 1658s, 1589s, 1467s, 1413s, 1368s, 1285m, 1183w, 1066w, 992w, 871m. $^1\text{H-NMR}$ (D_2O , 250 MHz): 3.09, 2.94 (2d, AB, J_{AB} = 13.5, CH_2); 1.39 (s, Me). MS: 118 (< 1, M^+), 89 (44), 73 (12), 42 (42).

(*R*)-2,3-Diamino-2-methylpropanoic Acid ((*R*)-1a). A mixture of (*R*)-6a (2.78 g, 8.52 mmol) in dioxane (10 ml) an 25% aq. HCl soln. (20 ml) was heated for 18 h at 100°, cooled to r.t., and evaporated. The residue was purified by ion-exchange chromatography (60 g of *Bio-Rad-50W-X8* resin) to yield, after drying over P_2O_5 under reduced pressure, 680 mg (67.6%) of (*R*)-1a. White solid. M.p. (dec.) 202–204°. [α]_D = –4.5 (MeOH, c = 0.2). IR (KBr): 3347m, 3279w (br.), 3106m (br.), 2972m, 2934m, 2555w (br.), 1640m (br.), 1598s, 1570s (br.), 1446w, 1404m, 1369m, 1337m, 1266w, 1215w, 1116w, 983m. $^1\text{H-NMR}$ (D_2O , 250 MHz): 3.47 3.37 (2d, AB, J_{AB} = 13.9, CH_2); 1.60 (s, Me). FAB-MS: 119.1 (20, [$M + \text{H}$]⁺), 109.1 (70), 91.2 (100).

Enantiomer (S)-1a. From (*S*)-6a (2.38 g, 7.29 mmol) as described for (*R*)-1a: 730 mg (84.4%) of (*S*)-1a. M.p. (dec.) 203–205°. [α]_D = +5.0 (MeOH, c = 0.2). Spectral data: in agreement with those for (*R*)-1a.

rac-2-Amino-2-(aminomethyl)-4-methylpentanoic Acid (rac-1b). A soln. of *rac-5b* (13.3 g, 46.6 mmol) in CF_3COOH (30 ml) was stirred for 1 h at 0° and at r.t. for 1 h. The solvent was evaporated, giving a white solid, which was stirred for 15 min in Et_2O (50 ml), filtered, and dried under high vacuum: 13.83 g (99.2%) of *rac-5-(aminomethyl)-5-(2-methylpropyl)imidazolidine-2,4-dione trifluoroacetate*. M.p. > 231° (dec.). IR (KBr): 3367m, 3170m, 3075m, 2963m, 1786m, 1710s, 1665s, 1626s, 1531w, 1414m, 1208s, 1177s, 1128s, 842m, 794m, 770m, 724m. $^1\text{H-NMR}$ (D_6)DMSO, 250 MHz): 11.05 (s, 1 NH); 8.07 (br. s, NH_3^+); 7.98 (s, 1 H); 3.10, 2.90 (AB, J_{AB} = 12.5, CH_2N); 1.7–1.45 (m, 3 aliph. H); 0.90, 0.82 (2d, J = 6.0, Me_2CH). MS: 185 (< 1, M^+), 156 (24), 113 (50), 69 (25), 45 (24), 30 (100). Anal. calc. for $\text{C}_{10}\text{H}_{16}\text{F}_3\text{N}_3\text{O}_4$ (299.25): C 40.14, H 5.39, N 14.04; found: C 39.87, H 5.38, N 13.83.

To a mixture of this trifluoroacetate (13.5 g, 45.1 mmol) and $\text{Ba}(\text{OH})_2 \cdot 8 \text{H}_2\text{O}$ (56.93 g, 180 mmol) in a steel autoclave was added H_2O (130 ml). The mixture was stirred for 48 h at 140°, cooled to r.t., and slowly acidified under vigorous stirring with 4N aq. H_2SO_4 to pH 1–2. The suspension was stirred on a steam bath for 1 h, cooled to r.t., and filtered and the precipitate (BaSO_4) washed with H_2O (100 ml). The amino acid in the filtrate was purified by ion-exchange chromatography (100 g of cation-exchange resin (*Bio-Rad, AG 50 W-X8*): 6.85 g (94.7%) of *rac-1b*. White powder. M.p. 224.5–226.5°. IR (KBr): 3355m, 3302m, 3039m, 2957s, 2872m, 2620m (br.), 1657m, 1605s, 1579s, 1430m, 1400s, 1340m, 1277m, 1190w, 957s, 860m, 756w, 529m. $^1\text{H-NMR}$ (D_2O , 250 MHz): 3.12, 2.85

($AB, J_{AB} = 13.5, CH_2N$); 1.8–1.5 ($m, 3$ aliph. H); 0.95, 0.90 ($2d, J = 6.5, Me_2CH$)₂. FAB-MS: 161 (100, $[M + H]^+$), 144 (17) 115 (16). Anal. calc. for $C_7H_{16}N_2O_2$ (160.22): C 52.48, H 10.07, N 17.49; found: C 52.19, H 9.80, N 17.38.

Enantiomer (R)-1b. A mixture of (*R*)-**6b** (1.0 g, 2.71 mmol), 25% aq. HCl soln. (4 ml), and dioxane (4 ml) was heated at 100° for 80 h, cooled to r.t., and poured onto ice (50 g), H₂O (75 ml), and Et₂O (50 ml). The aq. layer was extracted twice with Et₂O (50 ml), and then the H₂O was evaporated. The crude amino acid was purified by ion-exchange chromatography (20 g of *Bio-Rad, AG 50 W-X8* resin): 434 mg (93.5%) of (*R*)-**1b**. White powder. M.p. > 220° (dec.). $[\alpha]_D = +32.0$ (H₂O, $c = 0.2$). Spectra: in close agreement with those of *rac*-**1b**.

Enantiomer (S)-1b. As described for (*R*)-**1b**, with (*S*)-**6b** (2.3 g, 6.24 mmol), 25% aq. HCl (9 ml), and dioxane (9 ml): 30 g of *Bio-Rad, AG 50 W-X8*): 932 mg (93.2%) of (*S*)-**1b**. White powder. M.p. > 226° (dec.). $[\alpha]_D = -25.2$ (H₂O, $c = 0.2$). Spectra: in agreement with those of *rac*-**1b**.

tert-Butyl (2-Oxopropyl)carbamate (**4a**). To a stirred soln. of 2-[(*tert*-butoxy)carbonylamino]-*N*-methoxy-*N*-methylacetamide (**3**; 15.5 g, 71.0 mmol) in THF (20 ml) and Et₂O (150 ml) was added under Ar a soln. of MeMgCl (47.0 ml, 3M in Et₂O) at -40°. The suspension was allowed to come to 0°, stirred 1 h at 0° and overnight at r.t., and poured onto 2N aq. HCl (50 ml) and ice. The aq. phase was extracted with Et₂O, the combined org. fraction washed with sat. brine, dried (MgSO₄), and evaporated, and the residue chromatographed (SiO₂ (1 kg), toluene/AcOEt 1:1) to yield first, 2.40 g (15.5%) of **3** and, after bulb-to-bulb distillation under reduced pressure, 8.78 g (56.6% or 87.7% based on recovered **3**) **4a**. Colourless liquid. B.p. 65°/0.02 mbar. IR (film): 3364 m , 2979 m , 2931 w , 1725 s , 1711 s , 1515 s , 1456 w , 1367 s , 1285 m , 1251 m , 1165 s , 1077 w , 884 w . ¹H-NMR (250 MHz, CDCl₃): 5.23 (br. s , NH); 4.03 ($d, J = 4.7, CH_2$); 2.18 (s, Me); 1.45 ($s, t-Bu$). MS: 173 (< 1, M^+), 130 (8), 117 (8), 100 (8), 59 (30), 57 (100), 43 (21), 41 (36). Anal. calc. for $C_8H_{15}NO_3$ (173.21): C 55.47, H 8.73, N 8.09; found: C 55.43, H 8.73, N 8.35.

tert-Butyl (4-Methyl-2-oxopentyl)carbamate (**4b**). As described for **4a**, with **3** (15.5 g, 71 mmol) and 2M Me₂CHCH₂MgCl in Et₂O (88.75 ml, 177.5 mmol); 1 h at -40° 0.5 h at 0°, 5 h at r.t.). Workup with ice (100 g)/0.05N aq. HCl (200 ml)/Et₂O (200 ml), then brine (150 ml). Chromatography (SiO₂ (800 g), hexane/AcOEt 4:1) gave 11.93 g (78.1%) of **4b**. Colourless oil. A sample distilled at 65°/0.001 mbar for analysis. IR (KBr): 3373 m , 2960 s , 2932 m , 2873 m , 1711 s , 1504 s , 1367 s , 1279 s , 1250 s , 1168 s , 1014 m , 869 w , 781 w . ¹H-NMR (CDCl₃, 250 MHz): 5.26 (br. s , 1 NH); 3.99 ($d, J = 4.7, 2 H-C(1)$); 2.30 ($d, J = 6.7, 2 H-C(3)$); 2.25–2.05 ($m, H-C(4)$); 1.45 ($s, t-Bu$); 0.94 ($d, J = 6.5, Me_2CH$). MS: 159 (6), 142 (4), 130 (2), 117 (1), 85 (28), 57 (100), 41 (32).

rac-*tert*-Butyl [4-(4-Methyl-2,5-dioximidazolidin-4-yl)methyl]carbamate (*rac*-**5a**). A mixture of **4a** (8.78 g, 40.4 mmol), (NH₄)₂CO₃ (16.1 g, 141.6 mmol), and KCN (3.94 g, 60.6 mmol) in 70% aq. EtOH (200 ml) was stirred under Ar for 20 h at 50°, then cooled to 0°. A steady stream of Ar was passed through the soln. for 1 h. The mixture was poured onto ice and 1N aq. HCl (150 ml) and extracted (AcOEt), the org. phase washed (sat. brine), dried (MgSO₄), and evaporated, and the residue suspended in hexane, filtered, and dried under reduced pressure: 9.8 g (ca. 100%) of *rac*-**5a**. White powder which was not further purified. M.p. 197–198°. IR (KBr): 3384 m , 3331 m , 3203 (br.), 3069 w , 2979 w , 2935 w , 1727 s , 1705 s , 1529 w , 1454 w , 1393 m , 1369 m , 1346 w , 1307 w , 1276 w , 1248 m , 1171 m , 777 w . ¹H-NMR ((D₆)DMSO, 250 MHz): 10.58 (br. s , NH); 7.65 (br. s , NH); 6.84 (t' , $J = 6.3, CH_2NH$); 3.13 ($d, J = 6.3, CH_2NH$); 1.37 ($s, t-Bu$); 1.18 (s, Me). MS: 243 (< 1, M^+), 187 (3), 170 (10), 114 (66), 99 (8), 57 (100), 41 (27).

rac-*tert*-Butyl [4-(2-Methylpropyl)-2,5-dioximidazolidin-4-yl]methyl}carbamate (*rac*-**5b**). A mixture of (NH₄)₂CO₃ (21.52 g, 189 mmol), KCN (5.26 g, 80.9 mmol), and **4b** (11.60 g, 53.9 mmol) in 70% aq. EtOH was stirred at 50° overnight. The mixture was cooled to r.t. and poured onto ice (150 g), 1N aq. HCl (150 ml), and AcOEt (400 ml; HCN gas produced passed through bleach). The org. layer was extracted with sat. brine and dried (MgSO₄), the volume reduced to 200 ml, and the soln. left overnight at 0°. The white precipitate was filtered off and dried under high vacuum: 6.37 g (41%) of *rac*-**5b**. The filtrate was evaporated and chromatographed (SiO₂ (500 g), 5% MeOH/CHCl₃): further 7.21 g (46.9%) of *rac*-**5b**. M.p. 195–197°. IR (KBr): 3362 m , 3234 m , 2959 m , 2932 m , 2872 w , 1781 m , 1723 s , 1705 s , 1540 w , 1367 m , 1281 m , 1252 w , 1176 m , 992 w , 651 w . ¹H-NMR ((D₆)DMSO, 250 MHz): 10.59 ($s, 1$ NH); 7.60 ($s, 1$ NH); 6.80 (t' , $NHCH_2$); 3.11 ($d, J = 6.3, NHCH_2$); 1.65–1.4 ($m, 3$ aliph. H); 1.37 ($s, t-Bu$); 0.87, 0.78 ($2d, J = 6.4, Me_2CH$). MS: 229 (4), 217 (7), 156 (68), 113 (60), 57 (100), 41 (29), 30 (82). Anal. calc. for $C_{13}H_{23}N_3O_4$ (285.34): C 54.72, H 8.12, N 14.73; found: C 54.73, H 8.12, N 14.78.

rac-2,3-Bis(benzamido)-2-methylpropanoic Acid (*rac*-**6a**). To a mechanically stirred suspension of *rac*-**1a** (1.2 g, 10.0 mmol) in CH₂Cl₂ (25 ml) was added chlorotrimethylsilane (6.3 ml, 50.0 mmol) at r.t. The mixture was refluxed for 1 h and then cooled to r.t. (*i*-Pr)₂NEt (10.3 ml, 60.0 mmol) was added, the mixture refluxed for 1.5 h and then cooled to 0°. Benzoyl chloride (2.5 ml, 22 mmol) was added and the mixture stirred for 2 h at r.t. and poured onto ice, H₂O, and AcOEt. The aq. phase was extracted with AcOEt, the combined org. layer washed with sat. brine, dried (MgSO₄), and evaporated, and the residue crystallized from hexane/AcOEt to give, after drying under reduced pressure, 2.71 g (84%) of *rac*-**6a**. White powder. M.p. 198–199°. IR (KBr): 3320 m , 3063 w , 2943 w , 1739 s , 1653 s , 1620 m , 1600 m , 1575 m , 1544 s , 1489 m , 1448 w , 1320 m , 1213 w , 1120 w , 714 m . ¹H-NMR ((D₆)DMSO,

250 MHz): 12.48 (br. s, COOH); 8.67 (br. s, 2 NH); 7.9–7.75 (*m*, 4 arom. H); 7.6–7.4 (*m*, 6 arom. H); 3.9–3.7 (*m*, CH₂); 1.46 (*s*, Me). MS: 326 (< 1, *M*⁺), 281 (25), 105 (100), 77 (42).

(*R*)-2,3-Bis(benzamido)-2-methylpropanoic Acid ((*R*)-**6a**). To a stirred soln. of **8a** (4.77 g, 8.60 mmol) in toluene (50 ml) was added at 0° CF₃SO₃H (2.27 ml, 25.8 mmol) under Ar. The mixture was stirred for 4 h at 80° and then cooled to r.t. MeOH (50 ml) was added and the mixture stirred overnight at r.t. and evaporated. CH₂Cl₂ (100 ml) was added, the suspension stirred for 1 h and filtered, and the solid residue dried: 3.27 g (96%) of L-phenylalanine cyclohexylamide-trifluoromethanesulfonate as a white solid. The filtrate was evaporated, the residue dissolved in dioxane (40 ml), 3*N* aq. NaOH (30 ml) added at 0°, and the mixture stirred for 6 h at r.t. The mixture was acidified with 2*N* aq. HCl and extracted with AcOEt (3 × 75 ml), the combined org. fraction dried (MgSO₄) and evaporated, and the residue dried under reduced pressure. The white solid was suspended in Et₂O/hexane 1:1, the suspension stirred for 1 h and filtered, and the solid dried under reduced pressure: 2.71 g (96.4%) of (*R*)-**6a**. M.p. 193–195°. [α]_D²⁰ = +50.5 (MeOH, *c* = 0.2). IR (KBr): 3338*m* (br.), 3062*w*, 2994*w*, 2941*w*, 1725*m*, 1648*s*, 1621*s*, 1542*s*, 1457*w*, 1311*m*, 1254*m*, 1201*w*, 1151*w*, 714*m*. ¹H-NMR ((D₆)DMSO, 250 MHz): 12.47 (br. s, COOH); 8.8–8.6 (br. *m*, 2 NH); 7.9–7.75 (*m*, 4 arom. H); 7.6–7.4 (*m*, 6 arom. H); 3.9–3.65 (*m*, CH₂NH); 1.47 (*s*, Me). ISP-MS: 327.2 (100, [*M* + H]⁺).

Enantiomer (*S*)-**6a**. From **9a** (4.26 g, 7.658 mmol) as described for (*R*)-**6a**: 2.45 g (97.7%) of (*S*)-**6a**. M.p. 193.5–195.0°. [α]_D²⁰ = –49.0 (MeOH, *c* = 0.2). Spectral data: in agreement with those of (*R*)-**6a**.

rac-2-Benzamido-2-(benzamidomethyl)-4-methylpentanoic Acid (rac-**6b**). As described for *rac*-**6a**, with *rac*-**1b** (1.60 g, 10.0 mmol); reaction with benzoyl chloride for 3 h). The residue was suspended in Et₂O, filtered, and dried under reduced pressure: 3.10 g (86%) of *rac*-**6b**. White powder. M.p. 191–192°. IR (KBr): 3386*w*, 3063*w*, 3030*w*, 2958*w*, 2871*w*, 2600*w* (br.), 1723*m*, 1651*s*, 1530*s*, 1480*m*, 1366*w*, 1232*w*, 1154*w*, 713*m*. ¹H-NMR ((D₆)DMSO, 250 MHz): 12.8 (br. s, COOH); 8.39 (*t*, (br. s), NH); 8.17 (br. s, NH); 7.9–7.75 (*m*, 4 arom. H); 7.6–7.4 (*m*, 6 arom. H); 4.1–3.95, 3.9–3.75 (2*dd*, *ABX*, CH₂NHCOPh); 2.1–1.85 (*m*, 2 aliph. H); 1.85–1.65 (*sept.*, *J* = 6.5, 1 aliph. H); 0.91–0.85 (2*d*, *J* = 6.5, 6 aliph. H). MS: 368 (< 1, *M*⁺), 235 (10), 203 (18), 161 (16), 105 (100), 77 (42). Anal. calc. for C₂₁H₂₄N₂O₄: C 68.46, H 6.57, N 7.60; found: C 68.19, H 6.55, N 7.56.

(*R*)-2-Benzamido-2-(benzamidomethyl)-4-methylpentanoic Acid ((*R*)-**6b**). To a stirred soln. of **8b** (1 g, 1.76 mmol) in dry toluene (10 ml) under Ar was added CF₃SO₃O (0.46 ml, 5.23 mmol). The mixture was heated at 80° for 1.5 h and then cooled to r.t. MeOH (5 ml) was added, the mixture stirred for a further 1.5 h at r.t. and evaporated, the residue dissolved in AcOEt (150 ml), and the org. soln. washed with ice-cold 0.5*N* aq. HCl (2 × 75 ml) and sat. brine (75 ml). The org. layer was dried (MgSO₄) and evaporated. The residue was dissolved in THF/MeOH/H₂O 3:1:1 (10 ml) and LiOH·H₂O (221 mg, 5.28 mmol) added (further LiOH·H₂O (74 mg) was added after 1 h as the pH was *ca.* 7). The mixture was stirred for 12 h at r.t., the pH adjusted to 7 with 2*N* aq. HCl, and the org. solvents were evaporated. The residue was poured onto ice (50 g) and AcOEt (100 ml) and washed with 1*N* aq. HCl (2 × 75 ml). The org. layer was dried (MgSO₄) and evaporated and the residue washed with Et₂O (2 × 5 ml) and dried under high vacuum: 624 mg (96.3%) of (*R*)-**6b** as a white solid. As small sample was recrystallized from AcOEt/hexane for analysis. M.p. 217–218°. [α]_D²⁰ = –27.0 (MeOH, *c* = 0.28). IR (KBr): 3400*s*, 3064*m*, 3032*m*, 2956*s*, 2872*w*, 2600*w* (br.), 1726*s*, 1656*s*, 1544*s*, 1488*s*, 1449*m*, 1311*m*, 1220*m*, 711*m*, 600*m*. ¹H-NMR ((D₆)DMSO, 250 MHz): 12.79 (*s*, 1 COOH); 8.38 (*t*, *J* = 6.3, NHCH₂); 8.17 (*s*, 1 NH); 7.9–7.75 (*m*, 4 arom. H); 7.6–7.4 (*m*, 6 aliph. H); 4.02, 3.82 (2*dd*, *J*_{AB} = 13.7, *J*_{AX} = *J*_{BX} = 6.3, NHCH₂); 2.05–1.9 (*m*, CH₂CH); 1.75 (*sept.*, *J* = 6.2, Me₂CH); 0.91, 0.85 (2*d*, *J* = 7.5, Me₂CH). ISP-MS: 391 (27, [*M* + Na]⁺), 386 (53, [*M* + NH₄]⁺), 369 (100, [*M* + H]⁺). Anal. calc. for C₂₁H₂₄N₂O₄ (368.43): C 68.43, H 6.57, N 7.60; found: C 68.51, H 6.45, N 7.42.

Enantiomer (*S*)-**6b**. From **9b** (3.75 g, 6.59 mmol) as described for (*R*)-**6b**. Washing with Et₂O (2 × 7 ml) and drying under high vacuum yielded 2.3 g (94.7%) of (*S*)-**6b**. White solid. M.p. > 201° (dec.). [α]_D²⁰ = +31.5 (MeOH, *c* = 0.2). ¹H-NMR, IR, and MS: in close agreement with those of (*R*)-**6b**.

rac-4-(Benzamidomethyl)-4-methyl-2-phenyl-1,3-oxazol-5(4*H*)-one (rac-**7a**). A stirred soln. of *rac*-**6a** (2.7 g, 8.80 mmol) in Ac₂O (20 ml) was heated for 1 h at 90° and then evaporated. The residue was dissolved in toluene and evaporated (2–3 times). Drying under reduced pressure gave 2.44 g (100%) of *rac*-**7a**. White powder. M.p. 139–140°. IR (KBr): 3425*w* (br.), 3300*m*, 3066*w*, 2981*w*, 2934*w*, 2872*m*, 1814*s*, 1650*s*, 1602*w*, 1538*s*, 1451*m*, 1179*m*, 1006*s*, 911*w*, 696*s*. ¹H-NMR ((D₆)DMSO, 250 MHz): 8.66 (*t*, NH); 7.95–7.85 (*m*, 2 arom. H); 7.75–7.35 (*m*, 8 arom. H); 3.67 (*d*, *J* = 6.3, CH₂NHCOPh); 1.51 (*s*, Me). MS: 308 (< 1, *M*⁺), 175 (24), 134 (16), 105 (100), 77 (34). Anal. calc. for C₁₈H₁₆N₂O₃ (308.34): C 70.12, H 5.23, N 9.09; found: C 70.00, H 5.12, N 8.29.

rac-4-(Benzamidomethyl)-4-(2-methylpropyl)-2-phenyl-1,3-oxazol-5(4*H*)-one (rac-**7b**). As described for *rac*-**7a**, with *rac*-**6b** (3.10 g, 8.40 mmol) in Ac₂O (20 ml): 2.94 g (100%) of *rac*-**7b**. White powder. M.p. 114.5–115.0°. IR (KBr): 3432*m*, 3304*m*, 3065*w*, 3033*w*, 2931*m*, 2872*w*, 1813*s*, 1538*m*, 1490*m*, 1453*m*, 1318*m*, 1290*m*, 1169*w*, 990*m*, 883*w*, 699*m*. ¹H-NMR (CDCl₃, 250 MHz): 8.1–8.0 (*m*, 2 arom. H); 7.75–7.35 (*m*, 8 arom. H); 6.4–6.25 (*m*,

NHCH₂); 4.08, 3.72 (2*dd*, $J_{AB} = 7.0$, $J_{AX} = 13.0$, $J_{BX} = 14.0$, NHCH₂); 2.06, 1.92 (2*dd*, $J_{AB} = 6.0$, $J_{AX} = J_{BX} = 14.0$, CH₂CH); 0.92, 0.88 (2*d*, $J = 7.0$, Me₂CH). ISP-MS: 373 (38, [M + Na]⁺), 351 (85, [M + H]⁺), 23 (28), 201 (100). Anal. calc. for C₂₁H₂₂N₂O₃ (350.42): C 71.98, H 6.33, N 7.99; found: C 71.79, H 6.54, N 7.80.

(*S*)-N²-*f*(*R*)-2,3-Bis(benzamido)-2-methylpropanoylphenylalanine Cyclohexylamide (**8a**) and (*S,S*)-Isomer **9a**. A stirred soln. of *rac*-**7a** (2.44 g, 7.90 mmol) and (*S*)-phenylalanine cyclohexylamide (**2**; 2.9 g, 11.90 mmol) in *N*-methylpyrrolidin-2-one (14 ml) was heated for 20 h at 80°. After evaporation, the residue was chromatographed (SiO₂ (300 g), hexane/AcOEt 1:2) to yield first, after drying under reduced pressure, 1.87 g (42.7%) of **8a**. White solid. M.p. 180–180°. [α]_D = +25.4 (CHCl₃, $c = 1.0$). IR (KBr): 3410*m*, 3358*m*, 3060*w*, 2935*m*, 2852*w*, 1690*s*, 1673*s*, 1653*s*, 1536*s*, 1490*m*, 1455*w*, 712*m*. ¹H-NMR ((D₆)DMSO, 250 MHz): 8.63 (br. *s*, NH); 8.45–8.35 (*m*, NH); 8.0–7.8 (*m*, 3 arom. H); 7.8–7.75 (*m*, 2 arom. H); 7.6–7.4 (*m*, 5 arom. H, 1 NH); 7.25–7.1 (*m*, 5 arom. H); 4.5–4.4 (*m*, NHCH); 3.85–3.7 (*m*, NHCH); 3.65–3.4 (*m*, CH₂NHCOPh, 1 aliph. H); 3.25–3.15, 2.95–2.75 (2*m*, ABX, PhCH₂); 1.8–1.5 (*m*, 5 aliph. H); 1.4–1.0 (*m*, 5 aliph. H); 1.17 (*s*, Me). ISP-MS: 555.4 (100, [M + H]⁺), 456 (19).

Crystals suitable for X-ray analysis (*cf.* Table) were grown from MeCN.

Table. X-Ray Analysis of **8a**, **8b**, and **9b**

	8a	8b	9b
<i>Crystal data</i>			
Empirical formula	C ₃₃ H ₃₈ N ₄ O ₄	C ₃₆ H ₄₄ N ₄ O ₄ ·C ₃ H ₈ O ₂	C ₃₆ H ₄₄ N ₄ O ₄
Colour; habit	colourless, prismatic	colourless, prismatic	colourless, prismatic
Crystal size [mm]	0.45 × 0.45 × 0.75	0.45 × 0.50 × 0.5	0.15 × 0.50 × 0.65
Crystal system	hexagonal	monoclinic	orthorhombic
Space group	<i>P</i> 6 ₁	<i>P</i> 2 ₁	<i>P</i> 2 ₁ 2 ₁ 2 ₁
Unit cell dimensions			
<i>a</i> [Å]	9.340(3)	8.991(5)	10.429(4)
<i>b</i> [Å]		17.063(5)	11.330(4)
<i>c</i> [Å]	58.58(5)	25.266(5)	28.449(10)
β [deg.]		94.060(5)	
Volume [Å ³]	4426(4)	3867(2)	3361(2)
<i>Z</i>	6	4	4
Formula weight	554.7	596.8	596.8
Density (calc.)	1.25	1.26	1.18
Absorption coefficient [mm ⁻¹]	0.083	0.0268	0.616
<i>F</i> (000)	1776	640	1280
<i>Data collection</i>			
Radiation	MoK α	CuK α	CuK α
Temperatur [K]	223	300	183
2 θ Range [deg.]	0–56	0–112	0–112
Scan type	ω	2 θ - θ	2 θ - θ
Scan speed [deg./min]	1.1–14.65	1.0–20.0	2.4–15.0
Scan range [ω]	0.4	0.72	1.4
Independent reflexions	3681	5326	2534
Observed reflexions	2267	6200	2231
Absorption correction	none	none	none
<i>Solution and refinement</i>			
Solution	direct methods	direct methods	direct methods
Data-to-parameter ratio	6:1:1	5.7:1	5.6:1
Finel <i>R</i> index (obs. data)	6.17	8.24	4.40

Further elution of the column gave, after drying under reduced pressure, 1.60 g (36.5%) of **9a**. White solid. M.p. 179–180°. [α]_D = +21.3 (CHCl₃, $c = 1.0$). IR (KBr): 3412*m*, 3308*m*, 3063*w*, 3029*w*, 2933*m*, 2855*w*, 1649*s*, 1600*w*, 1580*w*, 1538*s*, 1450*m*, 1312*w*, 896*m*. ¹H-NMR ((D₆)DMSO, 250 MHz): 9.06 (br. *s*, NH); 8.79 (*r*', NH); 8.07 (*d*, $J = 8.5$, 1 arom. H); 7.95–7.85 (*m*, 4 arom. H); 7.65–7.45 (*m*, 5 arom. H, 1 NH); 7.41 (*d*, $J = 8.0$, NH); 7.2–7.0 (*m*, 5 arom. H); 4.5–4.4 (*m*, NHCH); 3.6–3.4 (*m*, NHCH, 1 aliph. H); 3.25–3.1, 2.95–2.8 (2*m*, ABX, PhCH₂); 1.8–1.5 (*m*, 5 aliph. H); 1.36 (*s*, Me); 1.3–1.05 (*m*, 5 aliph. H). MS: 555.5 (100, [M + H]⁺).

(*S*)-*N*²-[(*R*)-Benzamido-2-(benzamidomethyl)-4-methylpentanoyl]phenylalanine Cyclohexylamide (**8b**) and (*S,S*)-Isomer **9b**. As described for **8a** and **9a**, with *rac*-**7b** (2.93 g, 8.30 mmol), **2** (3.08 g, 12.5 mmol), and *N*-methylpyrrolidin-2-one (16 ml). Chromatography (SiO₂ (300 g), hexane/AcOEt 1:1→1:2) yielded first, after precipitation from hexane/AcOEt, 2.28 g (46.0%) of **8b**. Amorphous solid. M.p. > 86° (sint.). *R*_f (3% *i*-PrOH/Et₂O) 0.53. [α]_D = +2.5 (MeOH, *c* = 0.2). IR (KBr): 3420*m*, 3322*m*, 3063*w*, 3029*w*, 2931*m*, 2854*w*, 1645*s*, 1532*s*, 1485*s*, 1450*m*, 1308*m*, 699*m*. ¹H-NMR ((D₆)DMSO, 400 MHz): 8.22 (*s*, 1 NH); 8.15–8.05 (*m*, NHCH₂); 7.95 (*d*, *J* = 7.0, 1 NH); 7.87 (*d*, *J* = 7.0, 2 arom. H); 7.85–7.75 (*m*, 1 NH, 2 arom. H); 7.6–7.4 (*m*, 6 arom. H); 7.25–7.05 (*m*, 5 arom. H); 4.4–4.35 (*m*, PhCH₂CH); 3.94, 3.82 (2*dd*, *J*_{AB} = 14.0, *J*_{AX} = *J*_{BX} = 5.3, NHCH₂); 3.55–3.45 (*m*, 1 aliph. H); 3.1–3.0, 2.95–2.85 (2*m*, PhCH₂); 2.0–1.9 (*m*, 1 aliph. H); 1.75–1.6 (*m*, *ca.* 4 aliph. H); 1.6–1.5 (*m*, 1 aliph. H); 1.47 (*m*, Me₂CH); 1.3–1.05 (*m*, 6 aliph. H); 0.69, 0.60 (2*d*, *J* = 7.0, Me₂CH). ISP-MS: 619 (100, [*M* + Na]⁺), 597 (62, [*M* + H]⁺), 498 (15), 351 (71). Anal. calc. for C₃₆H₄₄N₄O₄ (596.77): C 72.46, H 7.43, N 9.39; found: C 72.65, H 7.62, N 9.30.

Crystals for X-ray determination (*cf.* Table) were grown from propane-1,2-diol.

Further elution of the column yielded 1.99 g (40.2%) of **9b**. Amorphous solid. M.p. 232–233°. *R*_f (3% *i*-PrOH/Et₂O) 0.12. [α]_D = +57.0 (MeOH, *c* = 0.1). IR (KBr): 3414*m*, 3306*m*, 3062*w*, 3029*w*, 2933*m*, 2856*w*, 1646*s*, 1536*s*, 1487*m*, 1450*w*, 1311*w*, 696*m*. ¹H-NMR ((D₆)DMSO, 400 MHz): 8.3–8.2 (*m*, 2 NH); 8.2–8.1 (*m*, NHCH₂); 7.90 (*s*, 1 NH); 7.77, 7.65 (2*d*, *J* = 7.0, 4 arom. H); 7.55–7.45 (*m*, 2 arom. H); 7.45–7.4 (*m*, 4 arom. H); 7.35 (*d*, *J* = 8.8, 2 arom. H); 7.23 (*t*, *J* = 7.5, 2 arom. H); 7.2–7.1 (*m*, 1 arom. H); 4.7–4.6, 4.6–4.5 (2*m*, CONHCH); 3.65–3.5 (*m*, NHCH₂); 3.15–3.05, 3.0–2.9 (2*m*, PhCH₂); 2.4–2.3 (*m*, 1 aliph. H); 1.8–1.65 (*m*, 6 aliph. H); 1.65–1.55 (*m*, 1 aliph. H); 1.35–1.1 (*m*, *ca.* 5 aliph. H); 0.68, 0.30 (2*d*, *J* = 7.0, Me₂CH). ISP-MS: 635 (11, [*M* + K]⁺), 619 (100, [*M* + Na]⁺), 597 (64, [*M* + H]⁺), 351 (73). Anal. calc. for C₃₆H₄₄N₄O₄ (596.77): C 72.46, H 7.43, N 9.39; found: C 72.34, H 7.71, N 9.29.

Crystals for X-ray determination (*cf.* Table) were grown from *i*-PrOH.

(*R*)-2-Amino-3-[(benzyloxy)carbonylamino]-2-methylpropanoic Acid ((*R*)-**10a**). To a stirred soln. of (*R*)-**1a** (560 mg, 4.74 mmol) in H₂O (4 ml) and 10% aq. Na₂CO₃ soln. (5.0 ml) was slowly added a soln. of *N*-[(benzyloxy)carbonyloxy]succinimide (1.30 g, 5.22 mmol) in dioxane (10 ml) at –20° and stirred for 1 h at –20°. The suspension was brought to 0°, stirred for 4 h (clear soln.), acidified with 0.5*N* aq. HCl, and stirred for 30 min at 0°. The mixture was filtered, the residue dried under reduced pressure, and the crude solid (1.30 g) purified by prep. HPLC (Lichrosorb RP 18, 5 × 25 cm, 100% H₂O (+0.1% CF₃COOH)→100% EtOH (+0.1% CF₃COOH) in 340 min): 900 mg (75.2%) of (*R*)-**10a**. White amorphous solid. [α]_D = +12.5 (MeOH, *c* = 0.2). IR (KBr): 3311*m* (br.), 3068*m* (br.), 3036*m*, 2951*m*, 2572*w* (br.), 1695*s*, 1673*s*, 1530*m* (br.), 1431*w*, 1370*w*, 1262*m*, 1199*m*, 1163*m*, 1024*w*, 697*w*. ¹H-NMR ((D₆)DMSO, 250 MHz): 8.30 (br. *s*, *ca.* 3 NH); 7.7–7.6 (*m*, CH₂NH₂); 7.45–7.25 (*m*, 5 arom. H); 5.1–4.95 (*m*, AB, PhCH₂O); 3.55–3.35 (*m*, CH₂NH₂); 1.39 (*s*, Me). ISP-MS: 253.3 (100, [*M* + H]⁺).

Also isolated were 130 mg (7.8%) of (*R*)-2,3-bis[(benzyloxy)amino]-2-methylpropanoic acid. Hygroscopic amorphous solid. [α]_D = +36.0 (MeOH, *c* = 0.2). IR (film): 3336*m* (br.), 3065*w*, 3033*w*, 2949*w*, 1708*s* (br.), 1554*m* (br.), 1454*w*, 1256*m* (br.), 1148*w*, 1073*w*, 697*w*. ¹H-NMR ((D₆)DMSO, 250 MHz): 12.59 (br. *s*, COOH); 7.5–7.2 (*m*, 10 arom. H, 2 NH₂); 5.1–4.9 (*m*, 2 PhCH₂); 3.6–3.5, 3.45–3.25 (2*m*, CH₂NH₂); 1.26 (*s*, Me). ISP-MS: 409.3 (40, [*M* + Na]⁺), 404.4 (80, [*M* + NH₄]⁺), 387.3 (100, [*M* + H]⁺), 343.3 (60).

Enantiomer (*S*)-**10a**. From (*S*)-**1a** (400 mg, 3.39 mmol) as described for (*R*)-**10a**: 641 mg (75%) of (*S*)-**10a**. [α]_D = –12.0 (MeOH, *c* = 0.2). Spectral data: in agreement with those of (*R*)-**10a**.

(*R*)-2-Amino-2-[(benzyloxy)carbonylaminoethyl]-4-methylpentanoic Acid ((*R*)-**10b**). A soln. of (*R*)-**1b** (200 mg, 1.25 mmol) in H₂O (0.8 ml) and 10% aq. Na₂CO₃ soln. (1.3 ml, 30.3 mmol) were stirred vigorously at 0°. To the mixture was added dropwise a soln. of *N*-[(benzyloxy)carbonyloxy]succinimide (343 mg, 1.38 mmol) in dioxane (2 ml). The resulting white suspension was stirred at 0° for 3 h and filtered and the white solid washed with dioxane/H₂O 1:1 (2 × 3 ml) and dried under high vacuum: 339 mg (92.1%) of (*R*)-**10b**. M.p. > 214° (dec). [α]_D = +40.0 (MeOH, *c* = 0.1). ¹H-NMR, IR, and MS: in close agreement with those of *rac*-**10b**.

Enantiomer (*S*)-**10b**. As described for (*R*)-**10b**, with (*S*)-**1b** (400 mg, 2.50 mmol), H₂O (1.6 ml), 10% aq. Na₂CO₃ soln. (2.66 ml, 30.3 mmol), *N*-[(benzyloxy)carbonyloxy]succinimide (686 mg, 2.75 mmol), and dioxane (4 ml). Washing with dioxane/H₂O 1:1 (2 × 5 ml): 505 mg (68.6%) of (*S*)-**10b**. The volume of the filtrate was reduced by half and kept at 0° overnight and the white precipitate filtered off and dried under high vacuum: further 201 mg (27.3%) of (*S*)-**10b**. M.p. > 214° (dec.). [α]_D = –39.1 (MeOH, *c* = 0.1). ¹H-NMR, IR, and MS: in close agreement with those of *rac*-**10b**.

(*R*)-3-[(Benzyloxy)carbonylamino]-2-[(tert-butoxy)carbonylamino]-2-methylpropanoic Acid ((*R*)-**11a**). To a stirred mixture of (*R*)-**10a** (450 mg, 1.78 mmol) and CH₂Cl₂ (5 ml) was added chlorotrimethylsilane (0.57 ml, 4.46 mmol). After 1.5 h stirring at 60° and cooling to 0°, (*i*-Pr)₂NEt (0.83 ml, 4.85 mmol) and di(*tert*-butyl)d carbonate (0.78 g, 4.85 mmol) were added. The mixture was stirred for 24 h at 60°, cooled to r.t., and evaporated. The residue

was extracted with Et₂O (25 ml) and ice-cold 0.1N aq. NaOH, the aq. layer acidified to pH 2 with 1N aq. HCl and reextracted with AcOEt (2 × 40 ml), and the combined org. phase dried (MgSO₄) and evaporated. The white solid was suspended in hexane, stirred for 30 min. filtered, and dried under reduced pressure: 440 mg (70.1%) of (*R*)-**11a**. $[\alpha]_D = +37.7$ (CHCl₃, *c* = 0.15). IR (KBr): 3371*m* (br.), 3068*w*, 2982*w*, 2942*w*, 2640*w* (br.), 1716*s*, 1523*w*, 1455*w*, 1399*w*, 1369*w*, 1254*m*, 1162*m*, 1074*w*. ¹H-NMR (CDCl₃, 250 MHz): 7.45–7.25 (*m*, 5 arom. H); 6.19 (br. *s*, NH); 5.50 (br. *s*, NH); 5.12 (*s*, PhCH₂O); 3.7–3.45 (*m*, CH₂NH₂); 1.53 (*s*, Me); 1.46 (*s*, *t*-Bu). ISN-MS: 351.3 (100, [M – H][–]), 277.3 (20).

Enantiomer (S)-**11a**. From (*S*)-**10a** (400 mg, 1.59 mmol) as described for (*R*)-**11a**: 459 mg (82%) of (*S*)-**11a**. $[\alpha]_D = -37.0$ (CHCl₃, *c* = 0.2). Spectral data: in agreement with those of (*R*)-**11a**.

(*R*)-2-[(*Benzoyloxy*)carbonylaminoethyl]-2-[(*tert*-butoxy)carbonylamino]-4-methylpentanoic Acid ((*R*)-**11b**). As described for (*R*)-**11a**, with (*R*)-**10b** (350 mg, 1.19 mmol), CH₂Cl₂ (6.5 ml), chlorotrimethylsilane (0.38 ml, 2.97 mmol; 1 h at 60°), (*i*-Pr)₂NEt (0.55 ml, 3.21 mmol), and di(*tert*-butyl)dicarbonat (519 mg, 2.38 mmol) in CH₂Cl₂ (1.5 ml; 20 h at 60°). Extraction with Et₂O (50 ml) and reextraction with AcOEt (2 × 50 ml). The white solid was dried under high vacuum: 397 mg (84.6%) of (*R*)-**11b**. M.p. 154.5°. $[\alpha]_D = -14.0$ (MeOH, *c* = 0.1). IR (KBr): 3421*m*, 3326*m*, 2966*m*, 2623*w* (br.), 1740*s*, 1699*s*, 1559*m*, 1497*s*, 1446*m*, 1403*m*, 1320*m*, 1272*s*, 1156*s*, 1067*m*, 740*w*, 697*w*, 546*w*. ¹H-NMR ((D₆)DMSO, 250 MHz): 12.80 (*s*, 1 COOH); 7.45–7.25 (*m*, 5 arom. H); 7.2–7.05 (*m*, NHCH₂); 6.31 (*s*, 1 NH); 5.1–4.9 (*m*, PhCH₂O); 3.55–3.4 (*d*, NHCH₂); 1.85–1.7 (*m*, 1 aliph. H); 1.7–1.5 (*m*, 2 aliph. H); 1.36 (*s*, *t*-Bu); 0.9–0.75 (*m*, Me₂CH). ISN-MS: 393 (100, [M – H][–]).

Enantiomer (S)-**11b**. From (*S*)-**10b** (350 mg, 1.19 mmol) as described for (*R*)-**11b**: 386 mg (82.3%) of (*S*)-**11b**. White solid. A small sample was recrystallized from MeCN for analysis. M.p. 159.8–160°. $[\alpha]_D = +15.0$ (MeOH, *c* = 0.1). ¹H-NMR, IR, and MS: in close agreement with those of (*R*)-**11b**.

REFERENCES

- [1] I. L. Karle, P. Balam, *Biochemistry* **1990**, *29*, 6747; P. Balam, *Curr. Opinion Struct. Biol.* **1992**, *2*, 845.
- [2] C. Spiegler, 'Synthesis and Conformational Studies of Peptides Containing Novel α,α -Disubstituted Amino Acids', Ph. D. Thesis, University of Zürich, 1993.
- [3] D. Obrecht, C. Spiegler, P. Schönholzer, K. Müller, H. Heimgartner, F. Stierli, *Helv. Chim. Acta* **1992**, *75*, 1666.
- [4] D. Obrecht, U. Bohdal, C. Broger, D. Bur, C. Lehmann, R. Ruffieux, P. Schönholzer, C. Spiegler, K. Müller, *Helv. Chim. Acta* **1995**, *78*, 563.
- [5] S. Nahm, S. Weinreb, *Tetrahedron Lett.* **1981**, 3815.
- [6] H. T. Bucherer, H. T. Fischbeck, *J. Prakt. Chem.* **1934**, *140*, 69; H. T. Bucherer, W. Steiner, *ibid.* **1934**, *140*, 291; H. Bergs, Ger. Pat. 566,094, 1929; *Chem. Zentralbl.* **1933**, *27*, 1001.
- [7] H. Kricheldorf, *Synthesis* **1970**, 592; K.-H. Altman, E. Altman, M. Mutter, *Helv. Chim. Acta* **1992**, *75*, 1198.
- [8] W. C. Still, M. Kahn, A. Mitra, *J. Org. Chem.* **1978**, *43*, 2923.
- [9] J. Mittendorf, W. Hartwig, Eur. Pat. Appl. EO 529,369, 1993.
- [10] C. M. Wilmot, J. M. Thornton, *J. Mol. Biol.* **1988**, *203*, 221; *Protein Eng.* **1990**, *3*, 479.
- [11] IUPAC-IUB Commission Biochemical Nomenclature, *Biochemistry* **1970**, *9*, 3471.
- [12] W. L. Bragg, J. C. Kendrew, M. F. Perutz, *Proc. R. Soc. London [Ser.] A* **1950**, *203*, 321.
- [13] E. J. Milner-White, *Biochem. Soc. Trans.* **1988**, *16*, 50; *J. Mol. Biol.* **1990**, *216*, 385; E. J. Milner-White, B. M. Ross, R. Ismail, K. Belhadj-Mostefa, R. Poet, *ibid.* **1988**, *204*, 777.
- [14] D. Bur (F. Hoffmann-La Roche AG, Basel), unpublished results.
- [15] J. S. Richardson, *Adv. Protein Chem.* **1981**, *34*, 167–339; J. S. Richardson, D. S. Richardson, in 'Prediction of Protein Structure and the Principles of Protein Conformation', Ed. G. D. Fasman, Plenum Press, New York, 1989, p. 1–98.
- [16] G. D. Rose, L. M. Gierasch, J. A. Smith, *Adv. Protein Chem.* **1985**, *37*, 1–109.
- [17] G. N. Ramachandran, V. Sasisekharan, *Adv. Protein Chem.* **1968**, *23*, 283–437; C. M. Venkatachalam, *Biopolymers* **1986**, *6*, 1425.
- [18] A. Perczel, M. A. McAllister, P. Császár, I. G. Csizmadia, *J. Am. Chem. Soc.* **1993**, *115*, 4849.
- [19] P. Gerber, K. Müller, *J. Comput.-Aided Mol. Design* **1995**, in press.